Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
复制标题
2013 年 ASCO/CAP 指南对乳腺癌双探针 Her-2 荧光原位杂交的评估产生的结果比 2007 年 ASCO/CAP 指南更加模棱两可
DOI：
10.1007/s10549-016-3917-6
复制
发表时间：
2016-08
影响因子：
3.8
通讯作者：
Fu L
中科院分区：
文献类型：
--
作者：
Qian XL;Wen HY;Yang YL;Gu F;Guo XJ;Liu FF;Zhang L;Zhang XM;Fu L
双探针荧光原位杂交（D-FISH）是一种被广泛接受的检测人表皮生长因子受体2（Her-2）基因扩增状态的方法。2013年，美国临床肿瘤学会/美国病理学家学会（ASCO/CAP）更新了浸润性乳腺癌（BCa）的Her-2检测指南。D-FISH的解释标准相应变更。在这项研究中，我们比较了基于2013年和2007年ASCO/CAP指南的Her-2 FISH状态，在我院进行Her-2 D-FISH检测的1931例BCa病例中。我们根据2013年ASCO/CAP指南分析了结果可疑病例的临床病理特征。尽管指南更新显著提高了Her-2扩增的检出率，但也显著增加了可疑结果的发生率，给临床管理带来了困境。可疑结果具有良好的重现性。D-FISH可疑病例的分布与Her-2免疫组化状态无关，表明Her-2 D-FISH可疑可能不反映Her-2过表达。与Her-2阴性组相比，Her-2 D-FISH阴性组Ki 67表达水平高，组织学分级高，淋巴结转移率高，雌激素受体α表达水平低，预后差。D-FISH检测Her-2不确定结果的临床意义值得进一步研究。
Dual-probe fluorescence in situ hybridization (D-FISH) is a widely accepted method to determine the gene amplification status of human epidermal growth factor receptor 2 (Her-2). In 2013, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on the Her-2 testing for invasive breast cancer (BCa). The interpretation criteria for D-FISH changed accordingly. In this study, we compared the Her-2 FISH statuses based on the 2013 and 2007 ASCO/CAP guidelines in 1931 cases of BCa with Her-2 D-FISH testing at our hospital. We analyzed the clinicopathologic features of cases with equivocal results by the 2013 ASCO/CAP guidelines. Although the guideline update significantly improved the detection rate of Her-2 amplification, it also significantly increased the rate of equivocal results, posing a dilemma for clinical management. The equivocal results had a good reproducibility. The distribution of D-FISH-equivocal cases did not correlate with Her-2 status by immunohistochemistry, suggesting that Her-2 D-FISH equivocality may not reflect Her-2 overexpression. Compared with Her-2-negative cases by D-FISH, Her-2 D-FISH-equivocal cases had higher Ki67 expression, higher histological grade, more frequent lymph node metastasis, and lower estrogen receptor α expression, indicating a group of BCa with worse prognosis. The clinical significance of Her-2-equivocal results by D-FISH warrants further investigation.
登录
查看更多内容
影响因子：
6.4
作者：
Bethune, Gillian C.;van Zanten, Daniel Veldhuijzen;Barnes, Penny J.
通讯作者：
Barnes, Penny J.
影响因子：
2.8
作者：
Pu, Xiaohong;Shi, Jiong;Ye, Qing
通讯作者：
Ye, Qing
影响因子：
5.8
作者：
Sapino, Anna;Maletta, Francesca;Marchio, Caterina
通讯作者：
Marchio, Caterina
DOI：
10.1093/jnci/95.2.142
发表时间：
2003-01-15
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Konecny, G;Pauletti, G;Slamon, DJ
通讯作者：
Slamon, DJ
影响因子：
45.3
作者：
Hammond, M. Elizabeth H.;Hayes, Daniel F.;Wolff, Antonio C.
通讯作者：
Wolff, Antonio C.